


# Author's Accepted Manuscript

Influenza Vaccination Increases Anti-Jc Virus Antibody Levels During Treatment With Natalizumab: Case Report

Jahir Andres Miranda Acuña, Bianca Weinstock-Guttman



PII: S2211-0348(16)30098-0  
DOI: <http://dx.doi.org/10.1016/j.msard.2016.06.014>  
Reference: MSARD427

To appear in: *Multiple Sclerosis and Related Disorders*

Received date: 24 February 2016  
Revised date: 7 May 2016  
Accepted date: 27 June 2016

Cite this article as: Jahir Andres Miranda Acuña and Bianca Weinstock-Guttman, Influenza Vaccination Increases Anti-Jc Virus Antibody Levels During Treatment With Natalizumab: Case Report, *Multiple Sclerosis and Related Disorders* <http://dx.doi.org/10.1016/j.msard.2016.06.014>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

# Influenza Vaccination Increases Anti-Jc Virus Antibody Levels During Treatment With Natalizumab: Case Report

Jahir Andres Miranda Acuña MD<sup>a,\*</sup>, Bianca Weinstock-Guttman MD<sup>b</sup>

<sup>a</sup>Department of Neurology. Hospital General Universitario Gregorio Marañón. Madrid, Spain.

<sup>b</sup>Professor of Neurology, University at Buffalo, Jacobs School of Medicine and Biomedical Sciences. Director, Jacobs MS Center for Treatment and Research. Director, Jacobs Pediatric MS Center of Excellence. Executive Director, New York State MS Consortium UBMD Neurology

\***Corresponding autor:** Jahir Miranda Acuña; Department of Neurology; Hospital General Universitario Gregorio Marañón; C/ Doctor Esquerdo, 46, 28007 Madrid, Spain. Tel: +34674388471. jahirmiranda@yahoo.com.co

## ABSTRACT

### Background

Natalizumab (NTZ) is an effective therapy for multiple sclerosis (MS). A common concern related to NTZ therapy is the risk of developing progressive multifocal leukoencephalopathy (PML).

### Clinical case

A patient that after seven years on NTZ therapy, testing on every 3 months repeated evaluations negative for anti-JCV status became positive (>3 units) 4 weeks after receiving influenza vaccine. Despite continuous therapy on NTZ for additional 2 years her anti-JCV index progressively declined to a level 0.6 units

### Conclusion

Our case raises the consideration to include vaccination as a factor that can affect JCV

Download English Version:

<https://daneshyari.com/en/article/5912123>

Download Persian Version:

<https://daneshyari.com/article/5912123>

[Daneshyari.com](https://daneshyari.com)